GlassScriptPhysician profile
Shannon Norman
NPI 1982881421
$1,102.60
in general payments reported to CMS, 2019-2025
10 companies · $653 in 2025
The $653 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $45.82 · 2021: $37.03 · 2022: $81.76 · 2023: $135 · 2024: $150 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $203.25 | 2023-2025 | Hemlibra |
| Novo Nordisk INC | $187.59 | 2019-2025 | Rebinyn, Novoseven, Novoeight |
| Genzyme Corporation | $159.97 | 2025 | |
| Genentech, INC. | $119.45 | 2023-2025 | Hemlibra |
| Kedrion Biopharma, INC. | $102.38 | 2025 | Ryplazim |
| Pfizer INC. | $90.51 | 2025 | |
| Octapharma USA, INC. | $81.76 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.82 | 2023-2025 | Advate |
| Csl Behring | $50.00 | 2025 | Hemgenix |
| Amgen INC. | $49.87 | 2019-2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Norman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.